The progress of AAV-mediated gene therapy in neuromuscular disorders

References

• Wang D, Zhong L, Nahid MA, et al. The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv. 2014;11:345–364.
   PubMed Web of Science ®Google Scholar
• Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Sci (80-.). 1965;149:754–756.
   PubMed Web of Science ®Google Scholar
• Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 1992;11:5071–5078.
   PubMed Web of Science ®Google Scholar
• Koczot FJ, Carter BJ, Garon CF, et al. Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA. PNAS. 1973;70:215–219.
   PubMed Web of Science ®Google Scholar
• Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. PNAS. 2010;107:10220–10225.
   PubMed Web of Science ®Google Scholar
• Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. PNAS. 1984;81:6466–6470.
   PubMed Web of Science ®Google Scholar
• Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 1989;63:3822–3828.
   PubMed Web of Science ®Google Scholar
• Jacobson SG, Cideciyan AV, Roman AJ, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372:1920–1926.
   PubMed Web of Science ®Google Scholar
• Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng. 2015;17:63–89.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994–2004.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther. 2015;23:192–201.
   PubMed Web of Science ®Google Scholar
• Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol. 2016;21:75–80.
   PubMed Web of Science ®Google Scholar
• Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. 1998;72:8568–8577.
   PubMed Web of Science ®Google Scholar
• McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8:1248–1254.
   PubMed Web of Science ®Google Scholar
• Hagedorn C, Schnödt M, Boehme P, et al. S/MAR element facilitates episomal long-term persistence of adeno-associated viral (AAV) vector genomes in proliferating cells. Hum Gene Ther. 2017;28:1169–1179.
   PubMed Web of Science ®Google Scholar
• Flanigan KM. The muscular dystrophies. Semin Neurol. 2012;32:255–263.
   PubMed Web of Science ®Google Scholar
• Koenig M, Hoffman EP, Bertelsons CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509–517.
   PubMed Web of Science ®Google Scholar
• Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–928.
   PubMed Web of Science ®Google Scholar
• England SB, Nicholson LV, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990;343:180–182.
   PubMed Web of Science ®Google Scholar
• Clemens PR, Krause TL, Chan S, et al. Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery. Hum Gene Ther. 1995;6:1477–1485.
   PubMed Web of Science ®Google Scholar
• Gregorevic P, Allen JM, Minami E, et al. Systemic delivery of rAAV6-microdystrophin preserves muscle function and extends lifespan in a murine model of severe muscular dystrophy. Nat Med. 2006;12:787–789.
   PubMed Web of Science ®Google Scholar
• Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. PNAS. 2000;97:13714–13719.
   PubMed Web of Science ®Google Scholar
• Watchko J, O’Day T, Wang B, et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther. 2002;13:1451–1460.
   PubMed Web of Science ®Google Scholar
• Yue Y, Pan X, Hakim CH, et al. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet. 2015;24:5880–5890.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med. 2010;363:1429–1437.
   PubMed Web of Science ®Google Scholar
• Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. 2012;20:443–455.
   PubMed Web of Science ®Google Scholar
• Yue Y, Ghosh A, Long C, et al. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther. 2008;16:1944–1952.
   PubMed Web of Science ®Google Scholar
• Kornegay JN, Li J, Bogan JR, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther. 2010;18:1501–1508.
   PubMed Web of Science ®Google Scholar
• Koo T, Okada T, Athanasopoulos T, et al. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J Gene Med. 2011;13:497–506.
   PubMed Web of Science ®Google Scholar
• Le Guiner C, Servais L, Montus M, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017; [cited 2017 July 25]. DOI:10.1038/ncomms16105.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kuhr CS, Allen JM, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther. 2007;15:1160–1166.
   PubMed Web of Science ®Google Scholar
• Rodino-Klapac LR, Montgomery CL, Bremer WG, et al. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther. 2010;18:109–117.
   PubMed Web of Science ®Google Scholar
• Xu R, Camboni M, Martin PT. Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism. Neuromuscul Disord. 2007;17:209–220.
   PubMed Web of Science ®Google Scholar
• Tsuchida K. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta Myol. 2008;27:14–18.
   PubMedGoogle Scholar
• Odom GL, Gregorevic P, Allen JM, et al. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther. 2008;16:1539–1545.
   PubMed Web of Science ®Google Scholar
• Pisani C, Strimpakos G, Gabanella F, et al. Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice. Biochim Biophys Acta. 2018; [cited 2018 April]. DOI:10.1016/j.bbadis.2018.01.030.
   PubMed Web of Science ®Google Scholar
• Chicoine LG, Rodino-Klapac LR, Shao G, et al. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates. Mol Ther. 2014;22:713–724.
   PubMed Web of Science ®Google Scholar
• McPherron AC, Lawler AM, Lee S-J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83–90.
   PubMed Web of Science ®Google Scholar
• Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1:6–15.
   Web of Science ®Google Scholar
• Haidet AM, Rizo L, Handy C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. PNAS. 2008;105:4318–4322.
   PubMed Web of Science ®Google Scholar
• Amthor H, Macharia R, Navarrete R, et al. Lack of myostatin results in excessive growth but impaired force generation. PNAS. 2007;104:1835–1840.
   PubMed Web of Science ®Google Scholar
• Mariot V, Joubert R, Hourdé C, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017; [cited 2017 Nov 30]. DOI:10.1038/s41467-017-01486-4.
   PubMed Web of Science ®Google Scholar
• Dumonceaux J, Marie S, Beley C, et al. Combination if myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther. 2010;18:881–887.
   PubMed Web of Science ®Google Scholar
• Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351:403–407.
   PubMed Web of Science ®Google Scholar
• Tabebordbar M, Zhu K, Cheng JKW, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351:407–411.
   PubMed Web of Science ®Google Scholar
• Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351:400–403.
   PubMed Web of Science ®Google Scholar
• El Refaey M, Xu L, Gao Y, et al. In vivo genome editing restores dystrophin expression and cardiac function in dystrophic mice. Circ Res. 2017;121:926–929.
   Web of Science ®Google Scholar
• Pini V, Morgan JE, Muntoni F, et al. Genome editing and muscle stem cells as a therapeutic tool for muscular dystrophies. Curr Stem Cell Rep. 2017;3:137–148.
   PubMedGoogle Scholar
• Bengtsson NE, Hall JK, Odom GL, et al. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun. 2017; [cited 2017 June 23]. DOI:10.1038/ncomms16007.
   Web of Science ®Google Scholar
• Wang JZ, Wu P, Shi ZM, et al. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD. Brain Dev. 2017;39:547–556.
   PubMed Web of Science ®Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595–605.
   PubMed Web of Science ®Google Scholar
• Cirak S, Feng L, Anthony K, et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther. 2012;20:462–467.
   PubMed Web of Science ®Google Scholar
• Goemans NM, Tulinius M, van den Hauwe M, et al. Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: results from an open-label extension study. PLoS One. 2016; [cited 2016 Sep 2]. DOI:10.1371/journal.pone.0161955.
   Web of Science ®Google Scholar
• Stefanovic B, Hackl W, Lührmann R, et al. Assembly, nuclear import and function of U7 snRNPs studied by microinjection of synthetic U7 RNA into Xenopus oocytes. Nucleic Acids Res. 1995;23:3141–3151.
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science. 2004;306:1796–1799.
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Babbs A, Wright J, et al. Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum Mol Genet. 2012;21:2559–2571.
   PubMed Web of Science ®Google Scholar
• Bish LT, Sleeper MM, Forbes SC, et al. Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther. 2012;20:580–589.
   PubMed Web of Science ®Google Scholar
• Vulin A, Barthélémy I, Goyenvalle A, et al. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther. 2012;20:2120–2133.
   PubMed Web of Science ®Google Scholar
• Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155–165.
   PubMed Web of Science ®Google Scholar
• Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27:59–65.
   PubMed Web of Science ®Google Scholar
• Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010;28:271–274.
   PubMed Web of Science ®Google Scholar
• Valori CF, Ning K, Wyles M, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010;2:35–42.
   Web of Science ®Google Scholar
• Benkhelifa-Ziyyat S, Besse A, Roda M, et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther. 2013;21:282–290.
   PubMed Web of Science ®Google Scholar
• Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Human Molecular Genetics. 2011;20:681–693.
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Richards AM, et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther. 2014;25:619–630.
   PubMed Web of Science ®Google Scholar
• Duque SI, Arnold WD, Odermatt P, et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol. 2015;77:399–414.
   PubMed Web of Science ®Google Scholar
• Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83:810–817.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713–1722.
   PubMed Web of Science ®Google Scholar
• Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29:285–298.
   PubMed Web of Science ®Google Scholar
• Hordeaux J, Wang Q, Katz N, et al. The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol Ther. 2018;26:664–668.
   PubMed Web of Science ®Google Scholar
• Flotte TR, Büning H. Severe toxicity in nonhuman primates and piglets with systemic high-dose administration of adeno-associated virus serotype 9-like vectors: putting patients first. Hum Gene Ther. 2018;29:283–284.
   PubMed Web of Science ®Google Scholar
• Lorson CL, Androphy EJ. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet. 2000;9:259–265.
   PubMed Web of Science ®Google Scholar
• Nirmal K, Singh NN, Androphy EJ, et al. Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol. 2006;26:1333–1346.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723–1732.
   PubMed Web of Science ®Google Scholar
• Gorman L, Mercatante DR, Kole R. Restoration of correct splicing of thalassemic β-globin pre-mRNA by modified U1 snRNAs. J Biol Chem. 2000;275:35914–35919.
   PubMed Web of Science ®Google Scholar
• Dal Mas A, Rogalska ME, Bussani E, et al. Improvement of SMN2 pre-mRNA processing mediated by exon-specific U1 small nuclear RNA. Am J Hum Genet. 2015;96:93–103.
   PubMed Web of Science ®Google Scholar
• Marquis J, Meyer K, Angehrn L, et al. Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol Ther. 2007;15:1479–1486.
   PubMed Web of Science ®Google Scholar
• Odermatt P, Trüb J, Furrer L, et al. Somatic therapy of a mouse SMA model with a U7 snRNA gene correcting SMN2 splicing. Mol Ther. 2016;24:1797–1805.
   PubMed Web of Science ®Google Scholar
• Mayer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther. 2015;23:477–487.
   PubMed Web of Science ®Google Scholar
• Victor M, Hayes R, Adams RD. Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the eyelids. N Engl J Med. 1962;267:1267–1272.
   PubMed Web of Science ®Google Scholar
• Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet. 1998;18:164–167.
   PubMed Web of Science ®Google Scholar
• Tomé FM, Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol. 1980;49:85–87.
   PubMed Web of Science ®Google Scholar
• Malerba A, Klein P, Bachtarzi H, et al. PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nat Commun. 2017;8:14848.
   PubMed Web of Science ®Google Scholar
• Strings V, Malerba A, Harbaran S, et al. “Silence and replace”: development of a single AAV vector system for the treatment of oculopharyngeal muscular dystrophy (OPMD). Hum Gene Ther. 2017;12:A1–A125.
   Google Scholar
• McEntagart M, Parsons G, Buj-Bello A, et al. Genotype-phenotype correlations in X-linked myotubular myopathy. Neuromuscul Disord. 2002;12:939–946.
   PubMed Web of Science ®Google Scholar
• Laporte J, Hu LJ, Kretz C, et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet. 1996;13:175–182.
   PubMed Web of Science ®Google Scholar
• Cui X, De Vivo I, Slany R, et al. Association of SET domain and myotubularin-related proteins modulates growth control. Nat Genet. 1998;18:331–337.
   PubMed Web of Science ®Google Scholar
• Taylor GS, Maehama T, Dixon JE. Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. PNAS. 2000;97:8910–8915.
   PubMed Web of Science ®Google Scholar
• Gurgel-Giannetti J, Zanoteli E, de Castro Concentino EL, et al. Necklace fibers as histopathological marker in a patient with severe form of X-linked myotubular myopathy. Neuromuscul Disord. 2012;22:541–545.
   PubMed Web of Science ®Google Scholar
• Buj-Bello A, Fougerousse F, Schwab Y, et al. AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis. Hum Mol Genet. 2008;17:2132–2143.
   PubMed Web of Science ®Google Scholar
• Childers MK, Joubert R, Poulard K, et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med. 2014; [cited 2014 Jan 22]. DOI:10.1126/scitranslmed.3007523.
   PubMed Web of Science ®Google Scholar
• Mack DL, Poulard K, Goddard MA, et al. Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. Mol Ther. 2017;25:839–854.
   PubMed Web of Science ®Google Scholar
• Hollinger K, Chamberlain JS. Viral vector-mediated gene therapies. Curr Opin Neurol. 2015;28:522–527.
   PubMed Web of Science ®Google Scholar
• Sintusek P, Catapano F, Angkathunkayul N, et al. Histopathological defects in intestine in severe spinal muscular atrophy mice are improved by systemic antisense oligonucleotide treatment. PLoS One. 2016; [cited 2016 May 10]. DOI:10.1371/journal.pone.0155032.
   PubMed Web of Science ®Google Scholar
• Somers E, Lees RD, Hoban K, et al. Vascular defects and spinal cord hypoxia in spinal muscular atrophy. Ann Neurol. 2016;79:217–230.
   PubMed Web of Science ®Google Scholar
• Hamilton G, Gilingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013;19:40–50.
   PubMed Web of Science ®Google Scholar
• Zhou H, Meng J, Marrosu E, et al. Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Hum Mol Genet. 2015;24:6265–6277.
   PubMed Web of Science ®Google Scholar
• Goncalves MA, van Nierop GP, Tijssen MR, et al. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J Virol. 2005;79:3146–3162.
   PubMed Web of Science ®Google Scholar
• Lostal W, Kodippili K, Yue Y, et al. Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum Gene Ther. 2014;25:552–562.
   PubMed Web of Science ®Google Scholar
• Koo T, Popplewell L, Athanasopoulos T, et al. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum Gene Ther. 2014;25:98–108.
   PubMed Web of Science ®Google Scholar